Aggregator

In Other Journals

2 months 2 weeks ago
Science, Volume 388, Issue 6744, Page 266-267, April 2025.
Corinne Simonti, and Jesse Smith, Keith T. Smith, Bianca Lopez, Caroline Ash, Yury Suleymanov, Priscilla N. Kelly, Marc S. Lavine, and Sarah Lemprière

Not a ‘DEI hire’

2 months 2 weeks ago
Science, Volume 388, Issue 6744, Page 330-330, April 2025.
Troy Christopher Dildine

Fatigue of Li metal anode in solid-state batteries

2 months 2 weeks ago
Science, Volume 388, Issue 6744, Page 311-316, April 2025.
Tengrui Wang, Bo Chen, Yijie Liu, Zhenyou Song, Zhongqiang Wang, Yuwei Chen, Qian Yu, Jiayun Wen, Yiming Dai, Qi Kang, Fei Pei, Rong Xu, Wei Luo, Yunhui Huang

Past, present, and future of serotonin-targeting therapeutics for Alzheimer's disease: Perspectives from DNA methylation

2 months 2 weeks ago
With population aging, Alzheimer's disease (AD) is becoming increasingly prevalent, causing great health and economic burdens worldwide. Despite decades of research, there are still no effective disease-modifying treatments for AD, highlighting the urgent need for more in-depth understanding of the disease-causing mechanisms. The brain serotonin (5-HT) neurotransmission system undergoes structural and functional changes in aging and AD, which contributes to cognitive decline and comorbid mood...
Yanzhi Liu

Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson's disease

2 months 2 weeks ago
Parkinson's disease is caused by the loss of dopamine neurons, causing motor symptoms. Initial cell therapies using fetal tissues showed promise but had complications and ethical concerns^(1-5). Pluripotent stem (PS) cells emerged as a promising alternative for developing safe and effective treatments⁶. In this phase I/II trial at Kyoto University Hospital, seven patients (ages 50-69) received bilateral transplantation of dopaminergic progenitors derived from induced PS (iPS) cells. Primary...
Nobukatsu Sawamoto

Phase I trial of hES cell-derived dopaminergic neurons for Parkinson's disease

2 months 2 weeks ago
Parkinson's disease is a progressive neurodegenerative condition with a considerable health and economic burden¹. It is characterized by the loss of midbrain dopaminergic neurons and a diminished response to symptomatic medical or surgical therapy as the disease progresses². Cell therapy aims to replenish lost dopaminergic neurons and their striatal projections by intrastriatal grafting. Here, we report the results of an open-label phase I clinical trial (NCT04802733) of an investigational...
V Tabar